Peptide library

What is
melanotan 2?

Melanotan 2, usually written melanotan II or MT-II, is a synthetic peptide that is not an approved medicine in the US or Australia and has no EU-wide authorisation. What it is, how it differs from two approved relatives, the adverse events that have been reported, and what regulators have done, as of November 2026.

Short answerCompound research · 7 min read · Updated 18 Nov 2026

Melanotan 2 (melanotan II, MT-II) is a synthetic, ring-shaped analogue of the hormone α-MSH that binds several melanocortin receptors. It is not an approved medicine: FDA considers it an unapproved new drug, the EMA lists no authorised medicine containing it, and Australia’s TGA says no product containing it is approved. Regulators have warned of serious adverse events.

Key takeaways

  • Melanotan 2 is a seven-amino-acid, ring-shaped analogue of α-MSH; in a 1997 cell study it bound the human MC1, MC3, MC4 and MC5 melanocortin receptors.
  • It is not afamelanotide (Scenesse), an approved medicine for adults with erythropoietic protoporphyria, and not bremelanotide (PT-141), which was developed from it and is the active ingredient of Vyleesi, a US prescription medicine; products sold online as “PT-141” are not that medicine.
  • FDA’s compounding page cites published case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism; the TGA warns of the risk of serious skin cancers.
  • In August 2026 the TGA reported inconsistent amounts of melanotan II in five seized nasal sprays carrying the same label, and 27 infringement notices for alleged unlawful supply.
  • Australia lists it in Schedule 4 (prescription only); the MHRA says it has acted for over 10 years to remove melanotan products that count as medicines from the UK market.

01Melanotan 2 at a glance

The short version, dated 18 November 2026.

QuestionMelanotan 2
What it isA synthetic peptide of seven amino acids, six of them closed into a ring: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. An analogue of alpha-melanocyte-stimulating hormone (α-MSH).
Other namesMelanotan II, MT-II. Not the same as melanotan I (afamelanotide).
Receptor targetsIn a 1997 cell study it bound the human MC1, MC3, MC4 and MC5 receptors.
Evidence on harmsT2: case reports and regulators’ adverse-event summaries.
United StatesNot approved. FDA has considered it an unapproved new drug since at least 2007.
European UnionNo EU-wide authorisation: no melanotan II medicine in the EMA’s data on centrally authorised medicines (17 Nov 2026).
United KingdomThe MHRA classes injectable and pen products as medicines and says it has acted for over 10 years to remove melanotan products that count as medicines (April 2024).
AustraliaSchedule 4 (prescription only) in the Poisons Standard October 2026. The TGA says no product containing it is included in the ARTG or approved for supply.
WADANot named on the 2026 or 2027 Prohibited List; check with your anti-doping organisation.

02What is melanotan 2?

Melanotan 2 is another way of writing melanotan II (MT-II), a synthetic peptide. A 1996 paper from the University of Arizona describes it as a cyclic heptapeptide analogue of α-MSH: seven amino acids, with a lactam bridge that closes six of them into a ring.

Melanocortin receptors come in five types, MC1R to MC5R. In a 1997 study in cells engineered to carry human receptors, melanotan II bound MC1R, MC3R, MC4R and MC5R (T4: binding in cells, not effects in people). According to the bremelanotide label, MC1R is found on melanocytes, the skin’s pigment cells, and MC4R on nerve cells in many areas of the brain and spinal cord.

This page describes what melanotan II binds and what regulators have recorded about it. How we grade evidence: evidence grades.

03How does melanotan 2 differ from afamelanotide and bremelanotide?

Three related peptides are often confused. Two are approved medicines, each for one use. Melanotan II is not.

Melanotan IIAfamelanotideBremelanotide (PT-141)
Structure7 amino acids, ring-shaped, amide end13 amino acids in a chain, an analogue of α-MSH7 amino acids, the same ring as melanotan II, free-acid end
Other namesMT-IIScenesse; cross-referenced as melanotan I in Australia’s Poisons StandardVyleesi
ReceptorsBound MC1R, MC3R, MC4R and MC5R in a cell studyBinds mainly MC1R (label)Activates several subtypes, most potently MC1R, then MC4R (label)
Approved?No (US, Australia); no EU-wide authorisationEU 2014, US 2019US 2019
Approved useNoneAdults with erythropoietic protoporphyria (EPP) who have had phototoxic reactionsOne diagnosed condition in premenopausal women
Skin warning on the labelNo labelMay darken existing moles and freckles; full-body skin checks twice a year recommendedDark patches on the face, gums or breasts in 1% of phase 3 participants, none on placebo, and in 38% in a separate study with more frequent use; more likely with darker skin; fading not confirmed in all

Products sold as melanotan II are neither of the approved medicines, and products sold online as “PT-141” are not Vyleesi. More on bremelanotide: PT-141 (bremelanotide).

04What adverse events have been reported with melanotan 2?

Events documented in people who used products sold as melanotan, regulators’ summaries of them, and those recorded in one small early study. Apart from that study, they come from reports, not controlled trials.

  • FDA. Its compounding page says that compounded melanotan II “may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities”, and that “Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.” In plain terms: immunogenicity is the risk of an immune reaction to the peptide, and the last three events are a form of brain swelling, over-stimulation of the nervous system, and a prolonged erection.
  • TGA (January 2025). “While the most common side effects include headache, nausea, vomiting, loss of appetite, and facial redness, the most concerning one is the risk of serious skin cancers. With melanotan-II, there have been reports of increased moles and freckles, kidney dysfunction and swelling of the brain.”
  • Moles and melanoma. A 2017 review of case reports on melanotan I and II found reports of changes in existing moles and of new, sometimes atypical (dysplastic) moles, and four case reports of melanomas arising from existing moles during or shortly after use. The authors wrote that conclusive evidence linking these events to melanotan is lacking.
  • UK reports. The MHRA received 16 UK suspected adverse drug reaction reports for melanotan II between 2012 and 2022. It notes that a report “does not necessarily mean that the events were caused by the product”, and that its scheme has “an unknown and variable level of reporting”.
  • Early study. In the 1996 pilot study, in 3 men over two weeks, mild nausea was recorded, and grade II sleepiness and fatigue in one participant.

Case reports show that an event happened after use. They cannot show how often it happens or, on their own, prove what caused it. How to read reports like these: side effects, documented vs unknown.

05What have regulators done about melanotan 2?

Australia. On 17 August 2026 the TGA said it had seized products suspected to contain melanotan II, and that its laboratory had confirmed the substance in them. Five seized nasal spray bottles with the same label held an estimated 73% to 180% of the labelled amount (our calculation from the TGA’s figures), and the TGA said the inconsistency “further increases the chance of adverse events”. It reported 27 infringement notices, totalling A$101,412 and paid in May 2026, issued to a New South Wales individual for the alleged unlawful supply of melanotan II. The TGA says melanotan II “is a prescription-only medicine in Australia and is not approved for use as a tanning agent”. More: are peptides legal in Australia?

United States. In August 2007 FDA sent a warning letter to a US company selling melanotan II, stating that, based on the company’s website, it was a new drug that could not be sold without an approved application. According to FDA’s 2016 notice, the company kept shipping it; its owner pleaded guilty in 2015 to conspiracy, and FDA proposed a permanent debarment. FDA’s Import Alert 66-41 lists melanotan I and II products from three named firms, in entries dated 2010 to 2019 (alert version published 17 November 2026); the entries for two of them note that the product was imported for non-human research and then “the unapproved new drug is sold on internet”. FDA’s compounding page lists melanotan II among substances “previously in category 2” whose nominations “were withdrawn by the nominators”, and keeps the risk statements quoted above. How FDA handles such products at the border: peptides, customs and import.

United Kingdom. In April 2024 the MHRA said products containing melanotan II are classed as medicines if they are injectable or pens, and a nasal spray only if it is sold with claims to treat or prevent disease. It said “the sale, supply and advertising of unauthorised medicines is not permitted under the Human Medicines Regulations”, and that it “has repeatedly taken action to remove Melanotan products from the market for over 10 years”, where products fall within the definition of a medicine. More: are peptides legal in the UK?

Sport. Melanotan II is not named on WADA’s 2026 or 2027 Prohibited List. The List’s S0 class covers substances with “no current approval by any governmental regulatory health authority for human therapeutic use”, and anti-doping organisations decide how it applies. See peptides and anti-doping.

06What we don’t know

  • How often the reported events happen. Case reports and the MHRA’s report counts cannot give a rate.
  • Whether melanotan II causes melanoma. The 2017 review found conclusive evidence lacking; the TGA warns of the risk of serious skin cancers.
  • What a given product contains. The TGA found inconsistent amounts across five bottles with the same label.
  • Its long-term effects. The published clinical studies we found are small and short, such as the 1996 pilot study of 3 men over two weeks (PubMed, 18 Nov 2026). A placebo-controlled phase 2 trial registered in February 2026 has posted no results (ClinicalTrials.gov NCT07437560, 18 Nov 2026).

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.

RefSources

  1. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (melanotan II entry, under “Bulk drug substances nominated but withdrawn”). Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  2. U.S. Food and Drug Administration. Notice of opportunity for hearing: proposal to debar (docket FDA-2015-N-4169), 5 Aug 2016, describing the August 2007 warning letter on melanotan II. Electronic Reading Room, content current as of 16 Sep 2016; read 18 Nov 2026. www.fda.gov/regulatory-information/electronic-reading-room/n…
  3. U.S. Food and Drug Administration. Import Alert 66-41: detention without physical examination of unapproved new drugs promoted in the U.S. (red-list entries for melanotan I and II). Import alert, published 17 Nov 2026; read 18 Nov 2026. www.accessdata.fda.gov/cms_ia/importalert_190.html
  4. Therapeutic Goods Administration. Melanotan II tanning peptide products found to be inconsistently dosed. Safety advisory, 17 Aug 2026; read on the Internet Archive capture of 8 Nov 2026, the newest (tga.gov.au timed out on 18 Nov 2026). www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  5. Therapeutic Goods Administration. Don’t risk using tanning products containing melanotan. Blog, 24 Jan 2025; read on the Internet Archive capture of 10 Nov 2026, the newest (tga.gov.au timed out on 18 Nov 2026). www.tga.gov.au/news/blog/dont-risk-using-tanning-products-co…
  6. Medicines and Healthcare products Regulatory Agency. FOI 24/274: side effects reports of melanotan II products. Freedom of information response, 17 Apr 2024; read 18 Nov 2026. assets.publishing.service.gov.uk/media/669fbd3aa3c2a28abb50d…
  7. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327): Schedule 4 entries for melanotan II and afamelanotide, and the index cross-references. Federal Register of Legislation, registered 30 Sep 2026; text searched 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  8. European Medicines Agency. Medicines data export (centrally authorised medicines), timestamp 17 Nov 2026: Scenesse (afamelanotide), authorised 22 Dec 2014; no melanotan II medicine. Dataset; searched 18 Nov 2026. www.ema.europa.eu/en/documents/report/medicines-output-medic…
  9. U.S. Food and Drug Administration. Scenesse (afamelanotide), prescribing information, revised 8/2024 (NDA 210797, approved 8 Oct 2019). Label, Drugs@FDA; read 18 Nov 2026. www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007…
  10. U.S. Food and Drug Administration. Vyleesi (bremelanotide), prescribing information, revised 10/2026 (NDA 210557). Label, Drugs@FDA; read 18 Nov 2026. www.accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005…
  11. Dorr RT, Lines R, Levine N, et al. [Pilot phase I study of melanotan II in 3 men.] Life Sci, 1996;58(20):1777–1784. PMID 8637402. pubmed.ncbi.nlm.nih.gov/8637402/
  12. Schiöth HB, Müceniece R, Mutulis F, et al. Selectivity of cyclic [D-Nal7] and [D-Phe7] substituted MSH analogues for the melanocortin receptor subtypes. Peptides, 1997;18(7):1009–1013. PMID 9357059. pubmed.ncbi.nlm.nih.gov/9357059/
  13. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol, 2017;56(10):975–980. PMID 28266027. pubmed.ncbi.nlm.nih.gov/28266027/
  14. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027). International Standard; both PDFs searched 18 Nov 2026. www.wada-ama.org/en/prohibited-list

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is melanotan 2 approved anywhere?

Not in the US or Australia, and it has no EU-wide authorisation. FDA considers it an unapproved new drug, the EMA lists no centrally authorised medicine containing it, and the TGA says no product containing it is approved for supply in Australia.

Is melanotan 2 the same as PT-141?

No. Bremelanotide (PT-141) was developed from melanotan II and shares its ring, but ends in a free acid where melanotan II ends in an amide. Bremelanotide is the active ingredient of Vyleesi, a US prescription medicine, and products sold online as “PT-141” are not that medicine; melanotan II is not approved.

Is melanotan 2 the same as afamelanotide or melanotan I?

No. Afamelanotide, cross-referenced as melanotan I in Australia’s Poisons Standard, is a 13-amino-acid chain approved as Scenesse for adults with erythropoietic protoporphyria. Melanotan II is a different, ring-shaped molecule.

What adverse events have been reported with melanotan 2?

FDA cites published case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism, and the TGA notes reports of increased moles and freckles, kidney dysfunction and swelling of the brain. Case reports cannot show how often these events happen.

Is melanotan 2 on WADA’s Prohibited List?

It is not named on the 2026 or 2027 List. The S0 class covers substances with no current approval for human therapeutic use; athletes in tested sport should check with their anti-doping organisation.

Why did the TGA test melanotan nasal sprays?

As part of an investigation, it seized products suspected to contain melanotan II. Its laboratory confirmed melanotan II and found inconsistent amounts across five bottles carrying the same label (August 2026).

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page